WSO - January 2024 - 33

Shahjouei et al.
33
Figure 1. Flowchart indicating the process of database screening and study selection for the systematic review and metaanalyses.
Please note that some studies were ineligible due to more than one criterion.
In AD-Design 1, among patients who received IVTtPA
within 4.5 h (Figure 3), 80.9% (CI: 65.7-93.0%;
unadjusted rate: 80.0%) had VA improvement by ⩾0.1
logMAR, 74.3% (CI: 60.9-86.0%; unadjusted rate:
73.2%) had ⩾0.3 logMAR VA improvement, and 39.0%
(CI: 25.6-53.1%; unadjusted rate: 39.2%) had a final
VA of ⩾20/100. SMCC of 77.1% logMAR (CI: 47.1-
107.1%) was reported after receiving IVT-tPA within
4.5 h.
Among patients who received IAT-tPA within 24 h
(Figure 4), 66.8% experienced ⩾0.1 logMAR improvement
(CI: 58.1-75.0%; unadjusted rate: 66.2%), 60.0%
(CI: 49.1-70.5%; unadjusted rate: 59.6%) had ⩾0.3 logMAR
VA improvement, 21.9% (CI: 14.1-30.7%; unadjusted
rate: 23.5%) had a final VA of 20/100 or more, and
SMCC was 76.9% (CI: 43.6-110.2%). Outcome of patients
who received IAT-UK within 24 h is available in
Supplementary sFigure 3.
In AD-Design 2 (Supplementary sFigures 4 to 8),
among those treated with IAT within 24 h, 61.9% (CI:
53.8-69.8%; unadjusted rate: 60.5%) had ⩾0.1 logMAR
improvement, 53.8% (CI: 39.3-68.1%; unadjusted rate:
48.4%) had ⩾0.3 logMAR improvement, 25.6%
(CI: 16.6-35.6%; unadjusted rate: 29.3%) had a final
VA of 20/200 or better, and SMCC was 66.4%
(CI: 48.8-84.1%).
Independent participant data analyses
To better explore the impact of moderators on the final VA,
16 IPD models adjusted for age were reported. As expected,
a shorter interval from visual loss to thrombolysis predicted
a better outcome (<12 h in most models). Except for IPDmodels
9-11 (VA improvement ⩾20/100), having at least 2
weeks follow-up before reporting the final VA was predictive
of outcome. In IPD-models 9-16, baseline logMAR
was suggestive of outcome (i.e. VA improvement ⩾20/100
and MC of logMAR). Antiplatelet therapy was an independent
predictor of ⩾0.1 logMAR improvement (IPDmodels
1-4), with marginal significance in ⩾0.3 logMAR
visual recovery.
Complications of thrombolytic therapy
Intra-ocular hemorrhage was observed in 4 (0.5%) patients
(all IAT).54-56 Ischemic stroke was reported in 5 (0.6%)56-58
and transient ischemic attacks in 10 (1.3%) patients (all
IAT).48,49,56,57,59,60 Symptomatic intracerebral hemorrhage
was reported in 8 (1.0%) patients following the interventions
(IAT-tPA: 423,56,61, IAT-UK: 136, combined IAT and
IVT-UK: 1,56 and IVT-UK: 262,63). One (0.1%) patient
passed following large intracerebral hematoma after receiving
IAT-UK.36
International Journal of Stroke, 19(1)

WSO - January 2024

Table of Contents for the Digital Edition of WSO - January 2024

Content
WSO - January 2024 - Cover1
WSO - January 2024 - Cover2
WSO - January 2024 - 1
WSO - January 2024 - Content
WSO - January 2024 - 3
WSO - January 2024 - 4
WSO - January 2024 - 5
WSO - January 2024 - 6
WSO - January 2024 - 7
WSO - January 2024 - 8
WSO - January 2024 - 9
WSO - January 2024 - 10
WSO - January 2024 - 11
WSO - January 2024 - 12
WSO - January 2024 - 13
WSO - January 2024 - 14
WSO - January 2024 - 15
WSO - January 2024 - 16
WSO - January 2024 - 17
WSO - January 2024 - 18
WSO - January 2024 - 19
WSO - January 2024 - 20
WSO - January 2024 - 21
WSO - January 2024 - 22
WSO - January 2024 - 23
WSO - January 2024 - 24
WSO - January 2024 - 25
WSO - January 2024 - 26
WSO - January 2024 - 27
WSO - January 2024 - 28
WSO - January 2024 - 29
WSO - January 2024 - 30
WSO - January 2024 - 31
WSO - January 2024 - 32
WSO - January 2024 - 33
WSO - January 2024 - 34
WSO - January 2024 - 35
WSO - January 2024 - 36
WSO - January 2024 - 37
WSO - January 2024 - 38
WSO - January 2024 - 39
WSO - January 2024 - 40
WSO - January 2024 - 41
WSO - January 2024 - 42
WSO - January 2024 - 43
WSO - January 2024 - 44
WSO - January 2024 - 45
WSO - January 2024 - 46
WSO - January 2024 - 47
WSO - January 2024 - 48
WSO - January 2024 - 49
WSO - January 2024 - 50
WSO - January 2024 - 51
WSO - January 2024 - 52
WSO - January 2024 - 53
WSO - January 2024 - 54
WSO - January 2024 - 55
WSO - January 2024 - 56
WSO - January 2024 - 57
WSO - January 2024 - 58
WSO - January 2024 - 59
WSO - January 2024 - 60
WSO - January 2024 - 61
WSO - January 2024 - 62
WSO - January 2024 - 63
WSO - January 2024 - 64
WSO - January 2024 - 65
WSO - January 2024 - 66
WSO - January 2024 - 67
WSO - January 2024 - 68
WSO - January 2024 - 69
WSO - January 2024 - 70
WSO - January 2024 - 71
WSO - January 2024 - 72
WSO - January 2024 - 73
WSO - January 2024 - 74
WSO - January 2024 - 75
WSO - January 2024 - 76
WSO - January 2024 - 77
WSO - January 2024 - 78
WSO - January 2024 - 79
WSO - January 2024 - 80
WSO - January 2024 - 81
WSO - January 2024 - 82
WSO - January 2024 - 83
WSO - January 2024 - 84
WSO - January 2024 - 85
WSO - January 2024 - 86
WSO - January 2024 - 87
WSO - January 2024 - 88
WSO - January 2024 - 89
WSO - January 2024 - 90
WSO - January 2024 - 91
WSO - January 2024 - 92
WSO - January 2024 - 93
WSO - January 2024 - 94
WSO - January 2024 - 95
WSO - January 2024 - 96
WSO - January 2024 - 97
WSO - January 2024 - 98
WSO - January 2024 - 99
WSO - January 2024 - 100
WSO - January 2024 - 101
WSO - January 2024 - 102
WSO - January 2024 - 103
WSO - January 2024 - 104
WSO - January 2024 - 105
WSO - January 2024 - 106
WSO - January 2024 - 107
WSO - January 2024 - 108
WSO - January 2024 - 109
WSO - January 2024 - 110
WSO - January 2024 - 111
WSO - January 2024 - 112
WSO - January 2024 - 113
WSO - January 2024 - 114
WSO - January 2024 - 115
WSO - January 2024 - 116
WSO - January 2024 - 117
WSO - January 2024 - 118
WSO - January 2024 - 119
WSO - January 2024 - 120
WSO - January 2024 - 121
WSO - January 2024 - 122
WSO - January 2024 - 123
WSO - January 2024 - 124
WSO - January 2024 - 125
WSO - January 2024 - 126
WSO - January 2024 - Cover3
WSO - January 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com